Sign up
Pharma Capital

Lifespot Health ahead of development for its cannabis vaporiser

The vaporiser is being developed by Seng Vital Pty Ltd, of which Lifespot owns 50%.
Modern Metal Electronic Cigarette E Cig Vaporizer and Cannabis
The vaporiser has the potential to be recognised as a medical device by the FDA

Lifespot Health Ltd (ASX:LSH) has entered the final phase of the development of the “reference standard” sample of the vaporiser for medical cannabis delivery.

The vaporiser allows cannabis to be taken in the form of vapors extracted from oils or herbs.

This phase of the project is expected to be completed by the end of July, well ahead of schedule and will be followed by commercialisation.

Software makes vaporise unique

What makes the vaporiser unique is its embedment in the medically certified software infrastructure of BodyTel GmbH, a wholly owned subsidiary of Lifespot.

The BodyTel infrastructure allows both patients and authorised physicians to retrieve and evaluate the readings and data collected by the vaporiser.

Large-scale market that is growing

With the all-in-one vaporiser integrated into the BodyTel system, Lifespot Health is addressing a large growth market.

Estimates state that the global market for legal cannabis applications will grow to over US$57 billion in annual revenue by 2027.

Of these, more than US$ 19 billion will be spent on medical cannabis applications.

Collaborating for funding

Collaboration with well-known international cannabis companies to secure further funding until the end of the September 2018 quarter, as well as sales cooperation, are advancing well.

Lifespot expects to remain ahead of schedule in both development and commercial milestones.



Register here to be notified of future LSH Company articles
View full LSH profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.